Skip to main content
Donald Landry, MD, Nephrology, New York, NY, New York-Presbyterian Hospital

DonaldW.LandryMDPhD

Nephrology New York, NY

Samuel Bard Professor and Chair, Columbia University Physician-in-Chief, NewYork Presbyterian/CUMC

Dr. Landry is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Landry's full profile

Already have an account?

Education & Training

  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Fellowship, Nephrology, 1985 - 1987
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1983 - 1985
  • Massachusetts General Hospital
    Massachusetts General HospitalInternship, Internal Medicine, 1983 - 1984
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 1983
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Nephrology

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1985 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1998

Publications & Presentations

PubMed

Abstracts/Posters

  • Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators
    Donald Landry, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Applied Therapeutics Closes Series A Financing
    Applied Therapeutics Closes Series A FinancingFebruary 14th, 2017
  • Applied Therapeutics Initiates Phase 1 Trial for AT-001 in Diabetic Complications
    Applied Therapeutics Initiates Phase 1 Trial for AT-001 in Diabetic ComplicationsFebruary 12th, 2018
  • Critics Find Dodgy Ethics in 'Three-Parent Baby' Conception
    Critics Find Dodgy Ethics in 'Three-Parent Baby' ConceptionSeptember 30th, 2016
  • Join now to see all

Grant Support

  • High-Activity Mutants Of Cocaine Esterase For Treatment Of Drug AddictionNational Institute On Drug Abuse2008–2011
  • Core--ChemistryNational Heart, Lung, And Blood Institute2007–2011
  • Metabolism In Heart Failure Translational Research CenterNational Heart, Lung, And Blood Institute2009–2010
  • Cocaine Catalytic Antibodies: Novel Technology For Demand ReductionNational Center For Research Resources1999

Hospital Affiliations